glp 1 agonist GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders The Buzz Around GLP-1 Agonists

Description

For patients who have not responded well to semaglutide or tirzepatide, or who have specific reasons to prefer a daily liraglutide regimen, Saxenda remains a valid clinical option

Further investigation is also needed in specific patient populations

Our findings indicate that GLP-1 secretion remains comparable between saline- and Donor+Cas9-treated DIO mice, suggesting that genome editing-mediated Exe4 secretion does not disrupt endogenous GLP-1 regulation (Supplementary Fig

This is the syringe most researchers prefer for semaglutide

The incretin effect of GLP-1 leads to a marked postprandial increase in circulating levels, which enhances insulin secretion.23,24 Elevated postprandial GLP-1 concentrations may be influenced by mechanical stimuli such as gastric distension,3,25 which also activates GLP-1-expressing neurons in the nucleus tractus solitarius (NTS).26 These responses may involve oxytocin-mediated vagal afferent signaling and contribute to the central GLP-1 systems role in promoting a negative energy balance.27,28 Beyond mechanical stimuli, classical satiety hormones, such as cholecystokinin, augment both central GLP-1 neuronal activity and peripheral GLP-1 release;29 however, the concentrations of cholecystokinin required to stimulate peripheral GLP-1 secretion may exceed physiological levels.30 GLP-1 secretion is modulated by various peptides, neurotransmitters, and nutrients, including carbohydrates, lipids, proteins, and amino acids, highlighting the complexity of its regulatory mechanisms.3,31 GLP-1 exerts its effects via the G-protein-coupled receptor,32,33 which is expressed on pancreatic beta cells as well as neurons within the central and peripheral nervous systems